EGFR and neoplasm: These results are critical as they demonstrate the ability of our approach to identify combinations capable of reducing tumor burden in animal models and suggest that clinically viable EGFR and FGFR inhibitor combinations such as lenvatinib and gefitinib48 warrant further detailed pharmacokinetic characterization in HNSCC.